About: Titan Pharmaceuticals

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Titan Pharmaceuticals Goto Sponge NotDistinct Permalink

An Entity of Type : yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FTitan_Pharmaceuticals&invfp=IFP_OFF&sas=SAME_AS_OFF

Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Attributes	Values
rdf:type	Thing company schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization Business enterprise yago:WikicatCompaniesBasedInSanMateoCounty,California yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates
rdfs:label	Titan Pharmaceuticals (en)
rdfs:comment	Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. (en)
foaf:name	Titan Pharmaceuticals (en)
name	Titan Pharmaceuticals (en)
foaf:depiction
dcterms:subject	Companies listed on the Nasdaq Companies based in South San Francisco, California Health care companies based in California Pharmaceutical companies of the United States
Wikipage page ID	7025125 (xsd:integer)
Wikipage revision ID	1105792851 (xsd:integer)
Link from a Wikipage to another Wikipage	Public company Companies listed on the Nasdaq Companies based in South San Francisco, California Health care companies based in California Pharmaceutical companies of the United States South San Francisco, California Pharmaceuticals
Link from a Wikipage to an external page	http://www.titanpharm.com
sameAs	Titan Pharmaceuticals Titan Pharmaceuticals Titan Pharmaceuticals Titan Pharmaceuticals
dbp:wikiPageUsesTemplate	dbt:Infobox_company dbt:R dbt:Reflist dbt:Start_date_and_age dbt:URL dbt:Use_dmy_dates dbt:Med-company-stub dbt:Pharmaceutical_companies_of_the_United_States
thumbnail	wiki-commons:Special:FilePath/Titan_pharmaceuticals_logo.png?width=300
founder	Louis R. Bucalo (en)
hq location	South San Francisco, California, U.S. (en)
industry	Pharmaceuticals
key people	Executive Chairman, Marc Rubin, MD; President & COO, Kate Beebe Devarney, Ph.D (en)
logo	Titan pharmaceuticals logo.png (en)
traded as	NASDAQ:TTNP (en)
type	Public company
has abstract	Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is placed subcutaneously, normally in the inner part of the upper arm, in a simple office procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting. Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder (OUD) in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. Current key ProNeura development programs include a Kappa Opioid Receptor Agonist (TP-2021) Implant for the treatment of moderate-to-severe chronic pruritus and a Nalmefene Implant for the prevention of relapse in OUD patients following detoxification from opioids. (en)
skos:closeMatch	http://www.grid.ac/institutes/grid.430734.7
prov:wasDerivedFrom	wikipedia-en:Titan_Pharmaceuticals?oldid=1105792851&ns=0
page length (characters) of wiki page	3035 (xsd:nonNegativeInteger)
founding year	1992-01-01 (xsd:gYear)
headquarter	South San Francisco, California
industry	Pharmaceuticals
type	Public company
foaf:isPrimaryTopicOf	wikipedia-en:Titan_Pharmaceuticals
is Link from a Wikipage to another Wikipage of	Iloperidone
is foaf:primaryTopic of	wikipedia-en:Titan_Pharmaceuticals

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 60 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software